The latest update is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).
On February 12, 2025, OKYO Pharma announced that its lead asset, OK-101, has been assigned the United States Adopted Name (USAN) ‘urcosimod’. This designation reflects OKYO’s progress in developing treatments for unmet needs in ophthalmology, particularly for NCP and DED. The naming signifies a milestone in urcosimod’s clinical development, which is currently in Phase 2 trials for NCP. The drug has shown promise with its dual anti-inflammatory and analgesic properties, distinguishing it from traditional treatments in ocular disease.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for treating neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). The company is committed to discovering novel molecules to address these severe ocular conditions, both of which currently lack FDA-approved treatments.
YTD Price Performance: -3.54%
Average Trading Volume: 130,052
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $37.27M
Learn more about OKYO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com